Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) and Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.
Insider and Institutional Ownership
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Recordati Industria Chimica E Farmaceutica has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Recordati Industria Chimica E Farmaceutica | 0 | 1 | 0 | 1 | 3.00 |
| Verrica Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
Verrica Pharmaceuticals has a consensus target price of $12.67, suggesting a potential upside of 264.61%. Given Verrica Pharmaceuticals’ higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Recordati Industria Chimica E Farmaceutica.
Valuation and Earnings
This table compares Recordati Industria Chimica E Farmaceutica and Verrica Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Recordati Industria Chimica E Farmaceutica | $2.96 billion | 4.10 | $501.92 million | $2.80 | 21.00 |
| Verrica Pharmaceuticals | $35.58 million | 1.68 | -$17.89 million | ($1.67) | -2.08 |
Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Recordati Industria Chimica E Farmaceutica and Verrica Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Recordati Industria Chimica E Farmaceutica | 18.38% | 33.73% | 12.76% |
| Verrica Pharmaceuticals | -102.84% | -407.11% | -70.17% |
Summary
Recordati Industria Chimica E Farmaceutica beats Verrica Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
